Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EDSA
stocks logo

EDSA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.267
-8.04%
--
--
-0.300
-37.5%
--
--
-0.300
-0%
Estimates Revision
The market is revising No Change the revenue expectations for Edesa Biotech, Inc. (EDSA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.20%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-33.20%
In Past 3 Month
Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.690
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 1.690
sliders
Low
5.00
Averages
5.00
High
5.00
H.C. Wainwright
Yi Chen
initiated
$5
2025-06-27
Reason
H.C. Wainwright
Yi Chen
Price Target
$5
2025-06-27
initiated
Reason
H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech with a Buy rating and $5 price target. Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company's lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.
Lucid Capital
Dev Prasad
Buy
initiated
$9
2025-05-23
Reason
Lucid Capital
Dev Prasad
Price Target
$9
2025-05-23
initiated
Buy
Reason
Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$21
2025-03-13
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$21
2025-03-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Edesa Biotech Inc (EDSA.O) is -1.45, compared to its 5-year average forward P/E of -2.66. For a more detailed relative valuation and DCF analysis to assess Edesa Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.66
Current PE
-1.45
Overvalued PE
-1.17
Undervalued PE
-4.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.97
Undervalued EV/EBITDA
-1.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.26
Current PS
0.00
Overvalued PS
9.41
Undervalued PS
-2.89
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EDSA News & Events

Events Timeline

(ET)
2025-10-28
07:51:10
Edesa Biotech Reports Successful Achievement of Primary Endpoint in Phase 3 Study of Paridiprubart
select
2025-04-04 (ET)
2025-04-04
16:17:27
Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-01Newsfilter
Edesa Biotech Reveals Schedule for Upcoming Conferences

  • Upcoming Conferences: Edesa Biotech, Inc. will participate in BIO-Europe in Vienna from November 3-5, 2025, and the LSX Investival Showcase Europe in London on November 17, 2025.

  • Company Focus: Edesa is a clinical-stage biopharmaceutical company developing treatments for immuno-inflammatory diseases, with a pipeline that includes therapies for Medical Dermatology and Respiratory conditions.

  • Key Products: The company is advancing EB06 for vitiligo and EB01 for Allergic Contact Dermatitis, while its respiratory candidate, paridiprubart, is aimed at treating Acute Respiratory Distress Syndrome and is being evaluated in a U.S. government-funded study.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding Edesa's future performance, emphasizing the risks and uncertainties that could affect the company's ability to achieve its goals.

[object Object]
Preview
9.0
10-28NASDAQ.COM
Edesa Biotech Announces Encouraging Phase 3 Outcomes for Paridiprubart in ARDS

  • Positive Phase 3 Study Results: Edesa Biotech reported that its drug candidate paridiprubart significantly reduced 28-day mortality in patients with Acute Respiratory Distress Syndrome (ARDS) during a Phase 3 study.

  • Comparison with Placebo: Patients receiving paridiprubart plus standard of care had a 39% risk of death, compared to 52% for those on placebo, indicating a 13% absolute improvement in survival and a 25% relative risk reduction.

  • Ongoing Research: Paridiprubart is also being tested in the U.S. government's Just Breathe study, which focuses on novel therapeutics for hospitalized adult ARDS patients.

  • Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
08-09NASDAQ.COM
Edesa Biotech Posts Narrower Loss in Q3

  • Earnings Report: Edesa Biotech reported a GAAP EPS loss of $(0.25) for Q3 FY2025, better than the expected $(0.26), with no revenue recognized due to its clinical-stage status and stable operating expenses of $1.9 million.

  • Clinical Development Focus: The company is prioritizing the development of EB06, an experimental treatment for vitiligo, while managing operational costs and leveraging government funding for ongoing clinical trials, particularly for its EB05 program.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Edesa Biotech Inc (EDSA) stock price today?

The current price of EDSA is 1.69 USD — it has decreased -1.92 % in the last trading day.

arrow icon

What is Edesa Biotech Inc (EDSA)'s business?

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

arrow icon

What is the price predicton of EDSA Stock?

Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Edesa Biotech Inc (EDSA)'s revenue for the last quarter?

Edesa Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Edesa Biotech Inc (EDSA)'s earnings per share (EPS) for the last quarter?

Edesa Biotech Inc. EPS for the last quarter amounts to -0.25 USD, decreased -51.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Edesa Biotech Inc (EDSA)'s fundamentals?

The market is revising No Change the revenue expectations for Edesa Biotech, Inc. (EDSA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.20%.
arrow icon

How many employees does Edesa Biotech Inc (EDSA). have?

Edesa Biotech Inc (EDSA) has 16 emplpoyees as of December 05 2025.

arrow icon

What is Edesa Biotech Inc (EDSA) market cap?

Today EDSA has the market capitalization of 12.41M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free